These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 36851890

  • 21. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, Butler MO, Minden MD, Hirano N.
    Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
    Zolov SN, Rietberg SP, Bonifant CL.
    Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
    Zhang H, Snyder KM, Suhoski MM, Maus MV, Kapoor V, June CH, Mackall CL.
    J Immunol; 2007 Oct 01; 179(7):4910-8. PubMed ID: 17878391
    [Abstract] [Full Text] [Related]

  • 26. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells.
    Dai Q, Han P, Qi X, Li F, Li M, Fan L, Zhang H, Zhang X, Yang X.
    Front Immunol; 2020 Oct 01; 11():539654. PubMed ID: 33281809
    [Abstract] [Full Text] [Related]

  • 27. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
    Zhang A, Sun Y, Wang S, Du J, Gao X, Yuan Y, Zhao L, Yang Y, Xu L, Lei Y, Duan L, Xu C, Ma L, Wang J, Hu G, Chen H, Wang Q, Hu L, Zhang B.
    Cytotherapy; 2020 Dec 01; 22(12):734-743. PubMed ID: 32684339
    [Abstract] [Full Text] [Related]

  • 28. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain.
    Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, Chang WC, Ostberg JR, Neman J, Jandial R, Portnow J, Forman SJ, Brown CE.
    Clin Cancer Res; 2018 Jan 01; 24(1):95-105. PubMed ID: 29061641
    [Abstract] [Full Text] [Related]

  • 29. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
    Nalawade SA, Shafer P, Bajgain P, McKenna MK, Ali A, Kelly L, Joubert J, Gottschalk S, Watanabe N, Leen A, Parihar R, Vera Valdes JF, Hoyos V.
    J Immunother Cancer; 2021 Nov 01; 9(11):. PubMed ID: 34815355
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
    Liu H, Lei W, Zhang C, Yang C, Wei J, Guo Q, Guo X, Chen Z, Lu Y, Young KH, Lu Z, Qian W.
    Clin Cancer Res; 2021 Jan 15; 27(2):473-484. PubMed ID: 33028589
    [Abstract] [Full Text] [Related]

  • 32. Distinct functions of CAR-T cells possessing a dectin-1 intracellular signaling domain.
    Liang X, Huang Y, Li D, Yang X, Jiang L, Zhou W, Su J, Chen N, Wang W.
    Gene Ther; 2023 May 15; 30(5):411-420. PubMed ID: 33953316
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model.
    Soltantoyeh T, Akbari B, Shahosseini Z, Mirzaei HR, Hadjati J.
    Front Immunol; 2024 May 15; 15():1362904. PubMed ID: 38855110
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector.
    Lee HJ, Hwang SJ, Jeong EH, Chang MH.
    J Microbiol; 2024 Jul 15; 62(7):555-568. PubMed ID: 38700775
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition.
    Yuti P, Wutti-In Y, Sawasdee N, Kongkhla K, Phanthaphol N, Choomee K, Chieochansin T, Panya A, Junking M, Yenchitsomanus PT, Sujjitjoon J.
    Int Immunopharmacol; 2022 Dec 15; 113(Pt B):109442. PubMed ID: 36435066
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.